SBL
KPTI icon

Sargent Bickham Lagudis’s Karyopharm Therapeutics KPTI Stock Holding History

Sargent Bickham Lagudis’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40
Closed -$6K – 965
2021
Q2 		$6K Hold
40
– – ﹤0.01% 778
2021
Q1 		$6K Hold
40
– – ﹤0.01% 774
2020
Q4 		$9K Buy
+40
New +$9.27K ﹤0.01% 671

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sargent Bickham Lagudis's KPTI Position: Q3 2021 in Review

Sargent Bickham Lagudis sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 40 shares — an estimated $6K sold.

Sargent Bickham Lagudis first reported a position in KPTI in Q4 2020 and held it in 3 quarters. The position peaked at $9K in Q4 2020. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • Sargent Bickham Lagudis reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 40 Karyopharm Therapeutics shares in Q3 2021, an estimated $6K.
  • Sargent Bickham Lagudis first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 3 quarters.
  • Sargent Bickham Lagudis's Karyopharm Therapeutics position peaked at $9K in Q4 2020.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2021, filed 5 Nov 2021.